Alexei Haceatrean

机构：Nicolae Testemițanu State University of Medicine and Pharmacy

发表论文 9 篇 · 总被引 35 次 · h-index 3

代表论文

• Phase Ib study of anti-mesothelin antibody drug conjugate anetumab ravtansine in combination with pegylated liposomal doxorubicin in platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. (2018 · Journal of Clinical Oncology · 被引 16)
• ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial (2026 · ˜The œLancet. Gastroenterology & hepatology · 被引 5)
• Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B (2023 · Journal of Hepatology · 被引 5)
• WED-365 Extended treatment of HBeAg+ CHB subjects with the Capsid assembly modulator ALG-000184 with or without Entecavir is associated with reductions in viral markers and favorable anti-HBeAb trends (2024 · Journal of Hepatology · 被引 3)
• THU-261 Monotherapy with the novel capsid assembly modulator ALG- 000184 for up to 96 weeks results in profound and sustained HBV DNA suppression in untreated subjects with chronic HBV infection (2025 · Journal of Hepatology · 被引 2)
• A Phase I Randomized Study of a Novel HBV Capsid Assembly Modulator, ALG-000184, in Participants with Chronic HBV Infection: Effects on Safety, HBV DNA and HBsAg Levels (2025 · SSRN Electronic Journal · 被引 2)